Research programme: dopamine reuptake inhibitors - Prexa

Drug Profile

Research programme: dopamine reuptake inhibitors - Prexa

Alternative Names: Mono-reuptake Inhibitors - Prexa; PRX-12205; PRX-12247; PRX-12266

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Prexa Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Neurological-disorders in USA (PO, Controlled release)
  • 06 Jul 2011 Research programme: dopamine reuptake inhibitors - Prexa is available for licensing as of 06 Jul 2011. http://prexainc.com
  • 06 Jul 2011 Early research in Neurological disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top